SEB Asset Management AB Invests $171.84 Million in Gilead Sciences, Inc. $GILD

SEB Asset Management AB bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,233,000 shares of the biopharmaceutical company’s stock, valued at approximately $171,843,000. Gilead Sciences comprises about 0.7% of SEB Asset Management AB’s holdings, making the stock its 23rd largest position.

A number of other institutional investors have also bought and sold shares of GILD. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences in the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC grew its stake in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC bought a new stake in Gilead Sciences in the fourth quarter worth approximately $26,000. Wealth Preservation Advisors LLC increased its holdings in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $28,000. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the transaction, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 77,000 shares of company stock valued at $9,978,740. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on GILD shares. Rothschild & Co Redburn reduced their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Truist Financial reduced their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Royal Bank Of Canada dropped their price objective on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Finally, Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Wednesday, May 20th. Twenty-six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $159.04.

Gilead Sciences Stock Down 1.5%

Gilead Sciences stock opened at $134.28 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $107.75 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm’s 50-day simple moving average is $129.73 and its 200 day simple moving average is $135.22. The stock has a market cap of $166.72 billion, a PE ratio of 18.29 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter last year, the firm earned $1.81 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts predict that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s payout ratio is currently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.